Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Free Cash Flow (2017 - 2025)

Cue Biopharma's Free Cash Flow history spans 9 years, with the latest figure at -$9.0 million for Q3 2025.

  • For Q3 2025, Free Cash Flow fell 19.9% year-over-year to -$9.0 million; the TTM value through Sep 2025 reached -$29.8 million, up 22.19%, while the annual FY2024 figure was -$36.4 million, 8.92% up from the prior year.
  • Free Cash Flow for Q3 2025 was -$9.0 million at Cue Biopharma, down from -$3.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$3.4 million in Q2 2025 and bottomed at -$12.9 million in Q2 2022.
  • The 5-year median for Free Cash Flow is -$10.0 million (2024), against an average of -$9.4 million.
  • The largest YoY upside for Free Cash Flow was 91.79% in 2021 against a maximum downside of 107.5% in 2021.
  • A 5-year view of Free Cash Flow shows it stood at -$10.6 million in 2021, then increased by 1.22% to -$10.5 million in 2022, then fell by 4.21% to -$11.0 million in 2023, then increased by 17.59% to -$9.0 million in 2024, then rose by 0.07% to -$9.0 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Free Cash Flow are -$9.0 million (Q3 2025), -$3.4 million (Q2 2025), and -$8.3 million (Q1 2025).